SCHEMBL22922550

SCHEMBL22922550

C[C@H](O)CN(C)C(=O)c1ccc(-c2c[nH]c3ncc(Br)cc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 3/20 0.53
▸ DYRK1A Q13627 3/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ JAK2 O60674 1/20 0.51
▸ ROCK2 O75116 1/20 0.51
▸ PRKD3 O94806 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ PRKCG P05129 1/20 0.51
▸ INSR P06213 1/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ FES P07332 1/20 0.51
▸ IGF1R P08069 1/20 0.51
▸ ROS1 P08922 1/20 0.51
▸ FGFR1 P11362 1/20 0.51
▸ PHKG2 P15735 1/20 0.51
▸ FER P16591 1/20 0.51
▸ FLT1 P17948 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ MARK3 P27448 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22922551 1.00 MAP4K1 (0.53) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL22922400 0.85 DYRK1A (0.60) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL24955708 0.84 DYRK1A (0.43) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL29216538 0.84 DYRK1A (0.43) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL21592950 0.78 MAP4K1 (0.56) MAP4K1SGK1AXLCAMKK2MAP3K11
SCHEMBL21592971 0.78 MAP4K1 (0.56) MAP4K1SGK1AXLCAMKK2MAP3K11
SCHEMBL21592940 0.78 MAP4K1 (0.61) MAP4K1SGK1AXLCAMKK2MAP3K11
SCHEMBL22922402 0.78 PLK4 (0.44) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL22922571 0.78 PLK4 (0.44) MAP4K1DYRK1APLK4AURKAJAK2
SCHEMBL22922569 0.78 PLK4 (0.44) MAP4K1DYRK1APLK4AURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459958-B2 Tricyclic compounds as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-11-04 — — US disclosed
CN-114127067-B Tricyclic compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-08-23 — — CN disclosed
CN-112239473-B Process for preparing tricyclic compounds as HPK1 inhibitors 百济神州(北京)生物科技有限公司 2023-12-08 — — CN disclosed
US-20220267354-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-08-25 — — US disclosed
CN-114127067-A Tricyclic compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-03-01 — — CN disclosed
WO-2021013083-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-01-28 — — WO disclosed
CN-112239473-A Tricyclic compounds as HPK1 inhibitors 百济神州(北京)生物科技有限公司 2021-01-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267354-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF ULK1, SBK1, PHKG1 MAP4K1 96/4885DYRK1A 1319/4885PLK4 156/4885
US-12459958-B2 Tricyclic compounds as HPK1 inhibitor and the use thereof ULK1, SBK1, PHKG1 MAP4K1 96/4885DYRK1A 1319/4885PLK4 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback